The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I study of the AKT inhibitor MK-2206 plus hormonal therapy in postmenopausal women with estrogen receptor positive (ER+) metastatic breast cancer (MBC).
Cynthia X. Ma
No relevant relationships to disclose
Feng Gao
No relevant relationships to disclose
Michael Naughton
No relevant relationships to disclose
Timothy J. Pluard
No relevant relationships to disclose
Steven Sorscher
No relevant relationships to disclose
Allison N Creekmore
No relevant relationships to disclose
Zhanfang Guo
No relevant relationships to disclose
Farrokh Dehdashti
No relevant relationships to disclose
Ben Ho Park
No relevant relationships to disclose
Albert C. Lockhart
No relevant relationships to disclose
L. Austin Doyle
No relevant relationships to disclose
Matthew J. Ellis
No relevant relationships to disclose
Bracha Erlanger
No relevant relationships to disclose